The technical committee of World Health Organization (WHO)granted Emergency Use Listing (EUL) to made in India Covid-19 vaccine Covaxin, reports The Economic Times.
WHO approves Bharat Biotech
The committee had on October 26 sought additional clarifications from Covaxin manufacturer Bharat Biotech. Bharat Biotech’s Covaxin and AstraZeneca and Oxford University’s Covishield are the two widely used vaccines in India.
This move will allow people inoculated with Covaxin to travel abroad without restrictions.
“This marks another successful milestone, more to come shortly,” Raches Ella, clinical lead, Covid-19 vaccines at Bharat Biotech tweeted after the WHO announced the grant of approval to Covaxin.
Major contention
Bharat Biotech chairman and managing director Krishna Ella, contended that the platform used to develop the inactivated virus vaccine was a well-established one, unlike the new technology of mRNA vaccines.
SAGE recommendation
Covaxin vaccine was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and recommended use of this vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above.
About Bharat Biotech
Hyderabad-based Bharat Biotech, which has developed Covaxin, submitted EOI (Expression of Interest) to the WHO on April 19 for the vaccine’s Emergency Use Listing (EUL). Covaxin demonstrated 77.8 per cent efficacy in its Phase 3 clinical trial.
Did you subscribe to our daily Newsletter?
It’s Free! Click here to Subscribe
Source: The Economic Times
